指南与共识骨质疏松与代谢性骨病

CTX-I与PINP作为骨转换标志物的使用:美国骨骼健康联盟关于标准化样本处理与患者准备以减少分析前变异性的推荐

Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.
指南 / 共识 · Osteoporos Int · 2017-06-19

美国骨骼健康联盟(NBHA)基于文献回顾与实践考虑,提出标准化样本处理和患者准备以减少I型胶原C端端肽(CTX-I)和I型前胶原N端前肽(PINP)分析前变异性的推荐。CTX-I样本须在空腹晨间采集,首选EDTA血浆;PINP采集条件要求较宽松。不可控因素(年龄、性别、妊娠、制动、近期骨折、合并症、抗骨质疏松药物等)应在解读时考虑。

要点

  • CTX-I须在空腹晨间采集,首选EDTA血浆以提高样本稳定性。
  • PINP昼夜变异小且不受进食影响,采集条件要求较宽松。
  • 年龄、性别、妊娠、制动、近期骨折、合并症及药物等不可控因素应在解读时考虑。

核心结论

  • 采用标准化的样本处理与患者准备程序将显著减少可控的分析前变异性。
  • 该推荐的成功实施需要实验室、医学界、试剂制造商和监管机构等全球多方利益相关者紧密合作。

研究设计与样本

  • 美国骨骼健康联盟(NBHA)骨转换标志物项目组基于对现有文献的回顾与实践考虑制定推荐。

主要发现

  • CTX-I样本必须在空腹晨间时段一致采集,EDTA血浆因样本稳定性更佳而为首选。
  • PINP的样本采集条件要求较不严格,因其昼夜变异极小且不受食物摄入影响。
  • 应遵守样本稳定性时限。
  • 不可控因素(年龄、性别、妊娠、制动、近期骨折、合并症、抗骨质疏松药物、其他药物)应在骨转换标志物解读时考虑。

关键数值与推荐

  • 国际骨质疏松基金会(IOF)与国际临床化学联合会(IFCC)骨标志物标准工作组已确定血PINP和CTX-I为骨折风险预测和骨质疏松治疗监测的骨转换参考标志物。

临床怎么用

  • CTX-I须在空腹晨间采集,首选EDTA血浆。
  • PINP采集条件要求较宽松,但仍应遵守样本稳定性时限。
  • 解读骨转换标志物时应考虑年龄、性别、妊娠、制动、近期骨折、合并症、抗骨质疏松药物及其他药物等不可控因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The National Bone Health Alliance (NBHA) recommends standardized sample handling and patient preparation for C-terminal telopeptide of type I collagen (CTX-I) and N-terminal propeptide of type I procollagen (PINP) measurements to reduce pre-analytical variability. Controllable and uncontrollable patient-related factors are reviewed to facilitate interpretation and minimize pre-analytical variability. INTRODUCTION: The IOF and the International Federation of Clinical Chemistry (IFCC) Bone Marker Standards Working Group have identified PINP and CTX-I in blood to be the reference markers of bone turnover for the fracture risk prediction and monitoring of osteoporosis treatment. Although used in clinical research for many years, bone turnover markers (BTM) have not been widely adopted in clinical practice primarily due to their poor within-subject and between-lab reproducibility. The NBHA Bone Turnover Marker Project team aim to reduce pre-analytical variability of CTX-I and PINP measurements through standardized sample handling and patient preparation. METHODS: Recommendations for sample handling and patient preparations were made based on review of available publications and pragmatic considerations to reduce pre-analytical variability. Controllable and un-controllable patient-related factors were reviewed to facilitate interpretation and sample collection. RESULTS: Samples for CTX-I must be collected consistently in the morning hours in the fasted state. EDTA plasma is preferred for CTX-I for its greater sample stability. Sample collection conditions for PINP are less critical as PINP has minimal circadian variability and is not affected by food intake. Sample stability limits should be observed. The uncontrollable aspects (age, sex, pregnancy, immobility, recent fracture, co-morbidities, anti-osteoporotic drugs, other medications) should be considered in BTM interpretation. CONCLUSION: Adopting standardized sample handling and patient preparation procedures will significantly reduce controllable pre-analytical variability. The successful adoption of such recommendations necessitates the close collaboration of various stakeholders at the global stage, including the laboratories, the medical community, the reagent manufacturers and the regulatory agencies.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Szulc P, Naylor K, Hoyle NR, et al. Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability. Osteoporos Int. 2017. PMID: 28631236. doi:10.1007/s00198-017-4082-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。